JPRN-UMIN000030955已完成2 期
Pembrolizumab as first-line therapy in poor performance status patients with advanced non-small-cell lung cancer highly expressing PD-L1: an open-label, single arm, multicenter, phase II study - Pembrolizumab in poor performance status patients
Department of allergy and respiratory medicine Okayama University Hospital0 个研究点目标入组 14 人开始时间: 2018年4月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) comordity of auto-immune disease 2) history of organ transplantation 3) symptomatic brain metastasis (patients with stable condition for more than 7days after radiation will be allowed.) 4) carcinomatous meningitis 5) presence of other cancer within 2 years of registration 6) presence of severe comordity
研究者
相似试验
已完成
不适用
Safety and efficacy of pembrolizumab as first-line treatment in non-small cell lung cancer patients with poor performance status: a pilot study.non-small cell lung cancerJPRN-UMIN000029601Hiroshima University Hospital30
已完成
不适用
Safety and efficacy of pembrolizumab as first-line treatment in elderly patients with non-small cell lung cancer: a pilot study.on-small cell lung cancerJPRN-UMIN000029602Department of Respiratory Internal medicine, Hiroshima Univestity Hospital35
招募中
2 期
Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPDNSCLC With COPDNCT05578222Tianjin Chest Hospital30
已完成
2 期
Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine CarcinomasHigh Grade Malignant Neuroendocrine Carcinoma (Diagnosis)NCT03136055University of California, San Francisco36
招募中
2 期
eo-adjuvant Pembrolizumab as an alternative treatment for MMRd uterine cancer, a phase II efficacy studyNL-OMON53535niversitair Medisch Centrum Groningen12